Brookline Capital Markets Estimates CRSP FY2028 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at Brookline Capital Markets decreased their FY2028 earnings estimates for shares of CRISPR Therapeutics in a research note issued on Tuesday, August 4th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings per share of $6.86 for the year, down from their prior forecast of $6.91. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($4.90) per share. Brookline Capital Markets also issued estimates for CRISPR Therapeutics’ FY2029 earnings at $35.29 EPS and FY2030 earnings at $127.36 EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative return on equity of 23.94% and a negative net margin of 3,368.72%.The company had revenue of $10.18 million for the quarter.

CRSP has been the topic of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. Evercore reaffirmed an “outperform” rating and issued a $76.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, July 8th. Citizens Jmp reiterated a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, July 6th. Finally, Morgan Stanley set a $60.00 target price on CRISPR Therapeutics and gave the company an “equal weight” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $68.11.

CRISPR Therapeutics Trading Up 7.1%

Shares of CRISPR Therapeutics stock opened at $53.07 on Wednesday. CRISPR Therapeutics has a 12-month low of $44.12 and a 12-month high of $78.48. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. The stock has a market cap of $5.12 billion, a PE ratio of -8.53 and a beta of 1.74. The company has a 50-day moving average of $52.54 and a two-hundred day moving average of $52.33.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CRSP. Cerity Partners LLC raised its position in shares of CRISPR Therapeutics by 3.0% in the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after buying an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp boosted its position in CRISPR Therapeutics by 3.0% during the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after acquiring an additional 200 shares during the last quarter. Allworth Financial LP grew its stake in CRISPR Therapeutics by 2.7% in the 4th quarter. Allworth Financial LP now owns 9,550 shares of the company’s stock worth $501,000 after acquiring an additional 249 shares during the period. Meeder Advisory Services Inc. grew its stake in CRISPR Therapeutics by 6.6% in the 4th quarter. Meeder Advisory Services Inc. now owns 4,392 shares of the company’s stock worth $230,000 after acquiring an additional 270 shares during the period. Finally, Hedges Asset Management LLC raised its holdings in CRISPR Therapeutics by 1.2% in the 4th quarter. Hedges Asset Management LLC now owns 22,775 shares of the company’s stock valued at $1,194,000 after acquiring an additional 275 shares during the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Naimish Patel sold 3,786 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the transaction, the insider owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. The trade was a 16.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.20% of the company’s stock.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Q2 results exceeded expectations: CRISPR reported a loss of $0.94 per share, narrower than the $1.19 analyst consensus, while revenue reached $10.18 million versus estimates of $7.45 million. Revenue increased more than tenfold year over year. CRISPR Therapeutics Q2 earnings report
• Positive Sentiment: Casgevy commercial momentum continued: Sales of the gene-editing therapy helped drive the revenue beat, with adoption expanding across global markets. The FDA also approved Casgevy for children as young as 2, broadening its potential patient population and long-term commercial opportunity. CRISPR Therapeutics business update and Q2 results
• Positive Sentiment: Several potential catalysts are approaching: Management highlighted a busy second half of 2026, including progress across clinical programs and upcoming siRNA data readouts. Investors viewed the expanding pipeline and planned milestones as supportive of the company’s growth outlook. CRISPR Therapeutics quarter and upcoming catalysts

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.